Atlas Trials

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

Clinical trial NCT05918302 · RECRUITING

Trial details

NCT number
NCT05918302
Sponsor
Grupo Espanol de Tumores Neuroendocrinos
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Neuroendocrine TumorsLung Neuroendocrine NeoplasmThymus Neoplasms
Start date
2023-10-27
Primary completion
2029-03-01
Enrollment
170

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.